Inclusive of all taxes
Doxofylline & Ambroxol Hydrochloride Tablets represent a specialized pharmaceutical formulation designed for effective respiratory therapy. Combining the bronchodilator effects of Doxofylline with the mucolytic properties of Ambroxol Hydrochloride, these tablets facilitate improved airway clearance and symptomatic relief in obstructive pulmonary diseases. Manufactured by IndiGlobal Exports under stringent WHO-GMP compliant conditions, these tablets are produced to meet export-quality standards ensuring batch-to-batch consistency, safety, and therapeutic reliability. The formulation is precisely dosed to optimize clinical outcomes in the treatment of respiratory illnesses such as asthma, chronic bronchitis, and other conditions characterized by excessive mucus production and bronchospasm. Packaged in export-grade blister or strip packs, the tablets maintain integrity and potency during transportation and storage, catering specifically to regulated and semi-regulated international pharmaceutical markets. Suitable for hospital use, retail pharmacy distribution, and institutional supply, this product aligns with international pharmacopoeial standards (IP/USP) and includes a shelf life that complies with regulatory frameworks. Doxofylline & Ambroxol Hydrochloride Tablets are thus a dependable pharmaceutical solution for medical professionals aiming to provide consistent and effective respiratory care.
Key Features
| Features | Description |
|---|---|
| Active Ingredients | Combination of Doxofylline and Ambroxol Hydrochloride |
| Therapeutic Use | Management of respiratory conditions including obstructive airway diseases |
| Dosage Form | Tablet |
| Manufacturing Standards | Produced in WHO-GMP compliant facilities |
| Packaging | Export-grade blister or strip packs |
| Quality Compliance | Meets IP/USP pharmacopoeial quality standards |
| Intended Markets | Export and regulated/semi-regulated pharmaceutical markets |
| Manufacturer | IndiGlobal Exports |
| Therapeutic Benefits | Bronchodilation and mucolytic action for airway clearance |
| Attributes | Description |
|---|---|
| Category | Respiratory |
| Formulation | Tablet |
| Active Pharmaceutical Ingredients (API) | Doxofylline and Ambroxol Hydrochloride |
| Packaging Type | Blister or strip packs suitable for export |
| Shelf Life | As per regulatory standards (typically 24 months) |
| Manufacturing Compliance | WHO-GMP certified manufacturing facility |
| Pharmacopoeial Standards | Conforms to Indian Pharmacopoeia (IP) and USP standards |
| Intended Use | Clinical treatment and ongoing respiratory care |
| Dosage Strength | Specific concentrations of Doxofylline and Ambroxol hydrochloride as per batch (subject to label) |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
These tablets provide dual-action therapy with Doxofylline acting as a bronchodilator to relax airway muscles and improve airflow, while Ambroxol Hydrochloride acts as a mucolytic agent facilitating mucus clearance from the respiratory tract.
Yes, Doxofylline & Ambroxol Hydrochloride Tablets are manufactured under WHO-GMP guidelines and comply with IP/USP standards, making them ideal for supply to regulated and semi-regulated international pharmaceutical markets.
The tablets are offered in export-grade blister or strip packs, designed to maintain drug stability and facilitate secure transportation for bulk and institutional orders.
The manufacturing process follows strict quality control protocols compliant with international regulatory standards, ensuring precise dosage accuracy in each tablet batch.
Yes, the formulation is suitable for ongoing clinical management of chronic respiratory conditions such as asthma and chronic bronchitis, supporting airflow improvement and mucus reduction.
Brand: indiglobal exports
Country Of Origin: India
Doxofylline & Ambroxol Hydrochloride Tablets is a pharmaceutical product indicated for respiratory treatment. This formulation is manufactured with export-quality standards to ensure therapeutic efficacy, consistent dosage, and compliance with international healthcare regulations.
Features:Doxofylline & Ambroxol Hydrochloride Tablets is developed for the effective management of respiratory conditions, offering reliable performance backed by stringent pharmaceutical standards. Each batch is carefully produced and tested to ensure consistency, safety, and compliance with global export norms.
This formulation supports the clinical treatment and ongoing care of patients with respiratory indications. Commonly prescribed in hospital and retail pharmacy settings, it ensures measurable therapeutic benefit.
Crafted in state-of-the-art facilities, this tablet formulation ensures accuracy in dosing and ease of administration. It is typically available in secure blister or strip packs suitable for bulk export or institutional supply.
The product is manufactured in facilities adhering to WHO-GMP standards and complies with pharmacopoeial quality benchmarks (IP/USP). Ideal for regulated and semi-regulated markets seeking quality-assured medications.
Inclusive of all taxes
You Save: 0
Panchkula , India
Service Provider , Professional Services, Exporter, Wholesaler
GST- 06eogps3248l1zf
